Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration.
Fiche du document
2013
- doi: 10.1007/s00417-012-2090-9
- issn: 0721-832X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00417-012-2090-9
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22733165
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1435-702X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_86D4134803676
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Jabs (Injections) Shots (Injections)Citer ce document
I. Mantel et al., « Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. », Serveur académique Lausannois, ID : 10.1007/s00417-012-2090-9
Métriques
Partage / Export
Résumé
PURPOSE: To investigate the rhythm and predictability of the need for retreatment with intravitreal injections of ranibizumab for neovascular age-related macular degeneration (nAMD). METHODS: This prospective study enrolled 39 patients with treatment-naïve nAMD. After three loading doses of intravitreal ranibizumab, patients underwent an intensified follow-up for 12 months (initially weekly, then with stepwise increases to every 2 weeks and to monthly after each injection). Patients were retreated on an as-needed basis if any fluid or increased central retinal thickness (CRT) (>50 μm) was found on spectral domain optical coherence tomography (OCT). Statistical analysis included patients who received at least two retreatments (five injections). RESULTS: A mean of 7.5 injections (range 0-12) were given between months 3 and 15. The mean visual acuity increased by 13.1 and 12.6 ETDRS letters at months 12 and 15 respectively. Two or more injection-retreatment intervals were found in 31 patients. The variability of their intra-individual intervals up to 14 weeks was small (SD 0-2.13 weeks), revealing a high regularity of the retreatment rhythm. The SD was correlated with the mean interval duration (r = 0.89, p < 0.001). The first interval was a good predictor of the following intervals (regression coefficient =0.81). One retreatment criterion was stable in 97 % of patients (cysts or subretinal fluid). CONCLUSION: The results of this study demonstrate a high intra-individual predictability of retreatment need with ranibizumab injections for nAMD. These findings may be helpful for developing individualized treatment plans for maintained suppression of disease activity with a minimum of injections and visits.